-
公开(公告)号:US20220160861A1
公开(公告)日:2022-05-26
申请号:US17552256
申请日:2021-12-15
申请人: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITE PARIS DIDEROT PARIS 7 , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
IPC分类号: A61K39/118 , A61P31/04 , G01N33/569
摘要: The invention relates to vaccine compositions for treating and/or preventing infections by a bacterium of the Chlamydiaceae family, said compositions comprising bacteria of the Chlamydiaceae family, which have been previously treated by at least one peptidoglycan inhibitor, or extracts of said treated bacteria.
-
公开(公告)号:US20220151780A1
公开(公告)日:2022-05-19
申请号:US17275428
申请日:2019-09-13
申请人: UNIVERSITE TECHNOLOGIE DE COMPIEGNE , UNIVERSITE PARIS EST CRETEIL VAL DE MARNE , ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
IPC分类号: A61F2/24
摘要: Implant (10) for a heart valve comprising two leaflets, particularly a mitral valve (MV), the implant (10) comprising: a clamp (11) comprising a body (13) and a jaw (14) rotationally hinged with the body (13) to pivot between an open position and a closed position in which the body (13) and the jaw (14) are able to clamp a first leaflet among the heart valve leaflets, so as to attach the implant (10) onto the first leaflet, a movement device (41, 42) comprising a pusher element (41), the movement device being configured to move the jaw (14) relative to the body (13) from the open position to the closed position or vice versa, when the pusher element (41) is pushed by a rod (101), and a balloon (12) attached to the clamp (11) and configured to close at least partially an open portion (O1) remaining between the heart valve (MV) leaflets during systole, when the implant (10) is attached to the first leaflet, so as to limit a reflux of blood through said open portion (O1) remaining during systole.
-
公开(公告)号:US20220131624A1
公开(公告)日:2022-04-28
申请号:US17571986
申请日:2022-01-10
发明人: Mathias Fink , Geoffroy Lerosey , Matthieu Dupre , Nadége Kaina
摘要: A wave shaping device which comprises a tunable impedance surface and a controller connected to the surface in order to control its impedance. The shaping device further comprises a transmission module for receiving a pilot signal used to control the impedance of the surface.
-
公开(公告)号:US20220125875A1
公开(公告)日:2022-04-28
申请号:US17422737
申请日:2021-01-20
申请人: INSTITUT PASTEUR , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
发明人: Saaid SAFIEDDINE , Christine PETIT
摘要: The present inventors report here, in the DFNB9 mouse model (OTOF knock-out mice), the first proof-of-principle that cochlear delivery of a fragmented cDNA via a dual-AAV vector approach can effectively and long-lastingly correct the profound deafness phenotype of these mice when administered well after their auditory system has matured (P30). The present invention therefore concerns a vector system that allows the expression of the full-length Otoferlin polypeptide, or of a functional fragment thereof, in inner hair cells, for use for treating patients suffering from DFNB9 deafness or preventing DFNB9 deafness in patients having DFNB9 mutations, wherein said patients are patients having a developed and mature auditory system, such as new born babies, toddlers, infants, teenagers or adults.
-
45.
公开(公告)号:US20220100050A1
公开(公告)日:2022-03-31
申请号:US17421843
申请日:2020-01-15
发明人: Pierre COLMAN , Alexandre PARRIAUX , Kamal HAMMANI , Guy MILLOT
摘要: A method for frequency-converting a source optical signal in order to produce a useful optical signal, by mixing a plurality of waves, implements a plurality of waveguides that are coupled together. Individual parameter values of the waveguides, as well as at least one coupling parameter, are selected so as to obtain the useful signal with a high intensity. Such a method for producing the useful signal is suitable for a spectroscopic application, in particular a molecular spectroscopy application.
-
公开(公告)号:US20220098552A1
公开(公告)日:2022-03-31
申请号:US17421840
申请日:2020-01-13
申请人: UNIVERSITÉ CÔTE D'AZUR , INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , CHU DE NICE
摘要: The method for tin vitro or ex vivo amplification of human adipose tissue stem cells includes: —extracting a stromal vascular fraction of a human adipose tissue including endothelial cells of the human adipose tissue vascular network and human adipose tissue stem cells, and an extracellular matrix of the human adipose tissue, the extracellular matrix including endothelial cells of the human adipose tissue vascular network, human adipose tissue stem cells and collagen; —mixing the stromal vascular fraction and the extracellular matrix; and—culturing the mixture obtained in the preceding step, in suspension, in a culture medium.
-
公开(公告)号:US20220097140A1
公开(公告)日:2022-03-31
申请号:US17426220
申请日:2020-01-28
申请人: AddUp , Centre National De La Recherche Scientifique (CNRS) , Ecole Normale Superieure Paris-Saclay
摘要: A process for the selective additive manufacture of a three-dimensional object from a layer of powder comprises: applying a layer of additive manufacturing powder to a support or to a previously consolidated layer, emitting a laser beam onto a first point of the layer of additive manufacturing powder so as to consolidate a first zone of the layer of powder comprising the first point, adjusting a power of the laser beam depending on an estimated temperature variation of the layer of powder at a second point, separate from the first point, and emitting a laser beam onto the second point with the adjusted power so as to consolidate a second zone of the layer of powder comprising the second point, the emission of the laser beam onto the first point and onto the second point being temporally separated by the predetermined time interval.
-
48.
公开(公告)号:US20220096426A1
公开(公告)日:2022-03-31
申请号:US17547501
申请日:2021-12-10
申请人: Institut National de Ia Sante et de Ia Recherche Medicale (INSERM) , Centre National de la Recherche Scientifique (CNRS) , Sorbonne Universite , Universite de Poitiers , Centre Hospitalier Universitaire de Poitiers
IPC分类号: A61K31/352 , A61P27/02 , A61P25/00 , A61K45/06 , C07D311/20 , C07D311/54
摘要: The present invention relates to a compound of the following general formula (I): or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.
-
49.
公开(公告)号:US11290231B2
公开(公告)日:2022-03-29
申请号:US16633283
申请日:2018-07-12
申请人: GREENERWAVE , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS— , ECOLE SUPÉRIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
IPC分类号: H04L5/00 , H04B17/309 , H01Q3/44 , H04B7/0404 , H04W88/08
摘要: A communication network includes an access point, a control unit in communication with the access point, a wave shaping device in communication with the control unit, and a wireless communication device. The control unit determines parameters of the wave shaping device, the parameters being search parameters if the control unit does not receive a pilot signal, and optimization parameters if the control unit receives a pilot signal.
-
公开(公告)号:US11285219B2
公开(公告)日:2022-03-29
申请号:US16745041
申请日:2020-01-16
发明人: Robert H. Zimmer , Gilles Guichard , Juliette Fremaux , Sebastien Goudreau , Claire Venin , Laura Mauran
IPC分类号: A61K47/59 , A61P3/00 , C07K7/02 , C07K14/605 , A61K38/00
摘要: The present description relates to peptidomimetic foldamers, and their synthesis. In particular, the description provides peptide-amino urea hybrid peptidomimetic foldamers comprising an alpha amino acid peptide portion and an oligourea portion.
-
-
-
-
-
-
-
-
-